A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 9,765 shares of SRRK stock, worth $426,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,765
Previous 9,765 -0.0%
Holding current value
$426,242
Previous $78,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$7.63 - $9.71 $129 - $165
-17 Reduced 0.17%
9,765 $78,000
Q2 2024

Jul 29, 2024

SELL
$7.84 - $16.79 $188 - $402
-24 Reduced 0.24%
9,782 $81,000
Q1 2024

Apr 25, 2024

SELL
$13.2 - $17.76 $68,125 - $91,659
-5,161 Reduced 34.48%
9,806 $174,000
Q4 2023

Jan 30, 2024

BUY
$6.52 - $20.32 $71,244 - $222,036
10,927 Added 270.47%
14,967 $281,000
Q3 2023

Oct 25, 2023

SELL
$6.02 - $7.76 $3,244 - $4,182
-539 Reduced 11.77%
4,040 $28,000
Q2 2023

Aug 07, 2023

SELL
$5.79 - $9.11 $2,738 - $4,309
-473 Reduced 9.36%
4,579 $34,000
Q1 2023

May 08, 2023

BUY
$7.36 - $12.72 $19,378 - $33,491
2,633 Added 108.85%
5,052 $40,000
Q1 2022

Apr 21, 2022

SELL
$11.89 - $24.68 $13,911 - $28,875
-1,170 Reduced 32.6%
2,419 $31,000
Q4 2021

Feb 01, 2022

SELL
$24.14 - $35.18 $1,762 - $2,568
-73 Reduced 1.99%
3,589 $89,000
Q3 2021

Nov 15, 2021

SELL
$27.38 - $42.21 $164 - $253
-6 Reduced 0.16%
3,662 $121,000
Q2 2021

Jul 30, 2021

BUY
$26.34 - $46.62 $1,369 - $2,424
52 Added 1.44%
3,668 $106,000
Q1 2021

May 03, 2021

BUY
$45.96 - $68.02 $55,014 - $81,419
1,197 Added 49.48%
3,616 $183,000
Q4 2020

Jan 28, 2021

BUY
$13.72 - $51.57 $33,188 - $124,747
2,419 New
2,419 $117,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.25B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.